Cutting-edge biotech Sangamo stock dives 13% after JPMorgan cites ‘growing skepticism’ in downgrade

Sangamo is developing innovative gene-editing programs for many devastating diseases, but a J.P. Morgan analyst called it a ‘show-me story from here.’